natgillin/translations-raw huggingface dataset:
Dose titration of candesartan cilexetil is recommended in patients with mild to moderate hepatic impairment before treatment with Atacand Plus (the recommended starting dose of candesartan cilexetil is 4 mg in these patients). 
Pred zdravljenjem z zdravilom Atacand Plus je bolnikom z blago do zmerno okvaro jeter odmerek cileksetilkandesartanata priporočljivo titrirati (priporočeni začetni odmerek cileksetilkandesartanata pri teh bolnikih je 4 mg).
There is no experience with the use of Atacand Plus in children (below the age of 18 years). 
Pri otrocih, mlajših od 18 let, ni izkušenj z uporabo zdravila Atacand Plus.
The antihypertensive effect of Atacand Plus may be enhanced by other antihypertensives. 
Druga antihipertenzivna zdravila lahko povečajo antihipertenzivni učinek zdravila Atacand Plus.
Exacerbation or activation of systemic lupus erythaematosus has been reported with the use of thiazide diuretics. 
Med uporabo tiazidnih diuretikov so poročali o poslabšanju ali aktiviranju sistemskega eritematoznega lupusa.
This medicinal product contains lactose, as an excipient, and patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Zato ga ne smejo prejemati bolniki z redkimi prirojenimi motnjami, kot so galaktozna intoleranca, laponska oblika zmanjšane aktivnosti laktaze ali malabsorbcija glukoze-galaktoze.
No additional accumulation of candesartan occurs after repeated doses of the combination compared to monotherapy. 
V primerjavi z monoterapijo se po ponavljajočih se odmerkih kandesartana ne pojavi dodatno kopičenje.
If this is severe, you may notice tiredness, weakness, irregular heartbear or pins and needles. 
Če so te spremembe hude, se vam lahko pojavi utrujenost, šibkost, neredno bitje srca ali mravljinčenje.
Medicines to control your heart beat (antiarrhythmic agents) such as digoxin and beta-blockers. 
• Zdravila za uravnavanje srčnega utripa (antiaritmike), npr. digoksin ali zaviralce beta.
Changes in how your liver is working, including inflammation of the liver (hepatitis).You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms. 
Pojavijo se vam lahko utrujenost, porumenelost kože in očesnih beločnic ter gripi podobni simptomi.
Candesartan cilexetil is a prodrug which is rapidly converted to the active drug, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. 
Cileksetilkandesartanat je predzdravilo, ki se med absorpcijo iz prebavil z estersko hidrolizo hitro spremeni v zdravilno učinkovino, kandesartan.
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system including AIIRAs, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. 
Pri takšnih bolnikih so uporabo zdravil, ki vplivajo na ta sistem, vključno z ARAII, spremljale akutna hipotenzija, azotemija, oligurija ali, redko, akutna odpoved ledvic.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with Angiotensin Converting Enzyme (ACE) inhibitors or hydrochlorothiazide. 
Med sočasno uporabo litija z zaviralci angiotenzinske konvertaze (ACE) ali hidroklorotiazida so poročali o reverzibilnem povečanju koncentracije litija v serumu in povečanju njegovih toksičnih učinkov.
Very rare Angioedema, rash, urticaria, pruritus 
Bolezni kože in podkožja zelo redki angioedem, izpuščaj, urtikarija, srbenje
HOW TO TAKE ATACAND PLUS 
KAKO JEMATI ZDRAVILO ATACAND PLUS
Very rare Hyperkalaemia, hyponatraemia 
Presnovne in prehranske motnje zelo redki hiperkaliemija, hiponatriemija
Sleep disturbances, depression, restlessness 
Psihiatrične motnje redki motnje spanja, potrtost, nemir
Very rare Nausea 
Bolezni prebavil zelo redki navzea
The half-life of hydrochlorothiazide remains unchanged (approximately 8 h) after administration of hydrochlorothiazide in combination with candesartan cilexetil. 
Po uporabi hidroklorotiazida v kombinaciji s cileksetilkandesartanatom ostane razpolovni čas hidroklorotiazida nespremenjen (približno 8 ur).
Hydrochlorothiazide crosses the placenta. 
Hidroklorotiazid prehaja skozi placento.
PHARMACEUTICAL FORM Tablet. 
FARMACEVTSKA OBLIKA tableta [Izpolni država članica]
This may make you feel faint or dizzy. 
Posledica je lahko omotica ali omedlevica.
Effects on the kidneys (such as regeneration, dilatation and basophilia in tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. 
Kandesartan je povzročil učinke na ledvicah (npr. regeneracijo, dilatacijo in bazofilijo v tubulih, povečanje koncentracije sečnine in kreatinina v plazmi).
HOW TO STORE ATACAND PLUS 
SHRANJEVANJE ZDRAVILA ATACAND PLUS
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy. 
Med zdravljenjem s tiazidnimi diuretiki je opisano povečanje koncentracije holesterola in trigliceridov.
The diuretic, natriuretic and antihypertensive effect of hydrochlorothiazide is blunted by NSAIDs. 
Nesteroidna protivnetna zdravila oslabijo diuretični, natriuretični in antihipertenzivni učinek hidroklorotiazida.
Common Increases in cholesterol and triglycerides 
Preiskave pogosti zvišanje holesterola in trigliceridov redki zvišanje sečnine in kreatinina v serumu
Respiratory distress (including pneumonitis and pulmonary oedema) 
Bolezni dihal, prsnega koša in mediastinalnega prostora redki dihalna stiska (vključno s pnevmonitisom in pljučnim edemom)
STATEMENT OF ACTIVE SUBSTANCE(S) [To be completed nationally] 
6.1 Seznam pomožnih snovi [Izpolni država članica]
Uncommon Anorexia, loss of appetite, gastric irritation, diarrhoea, constipation 
Bolezni prebavil občasni neješčnost, izguba apetita, draženje želodca, driska, zaprtost redki pankreatitis
Nausea. 
• Srbenje.
Cardiac arrhythmias 
• Mišični krči.
When indicated, induction of vomiting or gastric lavage should be considered. 
Če je indicirano, pride v poštev sprožitev bruhanja ali izpiranje želodca.
Toxic epidermal necrolysis, cutaneous lupus erythaematosus-like reactions, reactivation of cutaneous lupus erythaematosus 
Bolezni kože in podkožja občasni izpuščaj, urtikarija, fotosenzibilnost učinki redki toksična epidermalna nekroliza, kožnemu eritematoznemu lupusu podobne reakcije, reaktivacija kožnega eritematoznega lupusa
The absorption of hydrochlorothiazide is reduced by colestipol or cholestyramine. 
Holestipol in holestiramin zmanjšata absorpcijo hidroklorotiazida.
Respiratory, thoracic and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora zelo redki kašelj
Second and third trimesters of pregnancy (see sections 4.4 and 4.6) Severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2 BSA). 
Huda okvara ledvic (očistek kreatinina < 30 ml/min/1,73 m
There is no experience regarding the administration of Atacand Plus in patients with a recent kidney transplantation. 
Pri bolnikih z nedavno presajeno ledvico ni izkušenj z zdravilom Atacand Plus.
Stop taking Atacand Plus and seek medical help immediately if you have any of the following allergic reactions: difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat. 
Nehajte jemati zdravilo Atacand Plus in nemudoma poiščite zdravniško pomoč, če se vam pojavi katera od naslednjih alergijskih reakcij:
• Others (e.g. bepridil, cisapride, diphemanil, erythromycin iv, halofantrin, ketanserin, mizolastin, 
• nekaterimi drugimi zdravili (kot so npr. bepridil, cisaprid, difemanil, eritromicin iv.,
Jaundice (intrahepatic cholestatic jaundice) 
Bolezni jeter, žolčnika in žolčevodov redki zlatenica (intrahepatični holestatski ikterus)
The half-life of candesartan remains unchanged (approximately 9 h) after administration of candesartan cilexetil in combination with hydrochlorothiazide. 
Po uporabi cileksetilkandesartanata v kombinaciji s hidroklorotiazidom ostane razpolovni čas kandesartana nespremenjen (približno 9 ur).
Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy. 
V primeru prehoda z monoterapije s hidroklorotiazidom je odmerek cileksetilkandesartanata priporočljivo titrirati.
Thiazide diuretics may increase serum calcium levels due to decreased excretion. 
Tiazidni diuretiki lahko zaradi zmanjšanja izločanja kalcija povečajo njegovo koncentracijo v serumu.
Inflammation of the pancreas. 
• Vnetje trebušne slinavke.
Uncommon Postural hypotension Rare 
Očesne bolezni redki prehodno zamegljen vid
Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter. 
Po začetku sočasnega zdravljenja in občasno med zdravljenjem jim je treba kontrolirati delovanje ledvic.
Headache. 
• Glavobol.
Very rare Back pain, arthralgia, myalgia 
Bolezni mišično-skeletnega sistema in vezivnega tkiva zelo redki bolečine v hrbtu, artralgija, mialgija
OTHER Mon Tue Wed Thur Fri Sat Sun 
DRUGI PODATKI Pon Tor Sre Čet Pet Sob Ned
Itching. 
• Kašelj.
Necrotising angiitis (vasculitis, cutaneous vasculitis) 
Žilne bolezni občasni posturalna hipotenzija redki nekrotizirajoči angiitis (vaskulitis, kožni vaskulitis)
Common Respiratory infection 
Infekcijske in parazitske bolezni pogosti okužba dihal
Always take Atacand Plus exactly as your doctor has told you. 
Pri jemanju zdravila Atacand Plus natančno upoštevajte zdravnikova navodila.
Muscle spasm 
Cileksetilkandesartanat
Opening date:_________ 
Datum odprtja: __________
● Risk Management Plan (RMP) 
• Načrt za obvladovanje tveganj (RMP)
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1380/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/19/1380/001
Effect of food on oral absorption in healthy volunteers 
Vpliv hrane na peroralno absorpcijo pri zdravih prostovoljcih
Carcinogenicity studies did not reveal special hazards for humans. 
Študije kancerogenosti ne kažejoposebnega tveganja za človeka.
Bottles showing any visible settling should be vigorously shaken for a minimum of 10 seconds. 
Stekleničke, v katerih je vidna usedlina, je treba najmanj 10 sekund močno stresati.
If you have missed a dose, take it as soon as you remember and then carry on as before. 
Če ste izpustili odmerek zdravila, ga zaužijte takoj, ko se spomnite, in potem nadaljujte z jemanjemzdravila kot prej.
It is used to prevent and treat many different fungal infections. 
Uporablja se za preprečevanje in zdravljenještevilnih različnih vrst glivnih okužb.
EXP Discard after 30 days of opening. 
EXP Zavrzite 30 dni po odprtju.
§ See section 4.4. 
§Glejte poglavje 4.4.
The elimination half-life (t1/2) was prolonged from approximately 27 hours up to ~43 hours in respective groups. 
Eliminacijski razpolovni čas (t1/2) se je v zadevnih skupinah podaljšal s približno 27 ur na vse do približno 43 ur.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začelijemati katero kolidrugo zdravilo.
These findings are not necessarily indicative of a potential for functional changes in humans. 
Ti izsledki ne pomenijo nujno možnostiza funkcionalne spremembe pričloveku.
It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with Aspergillus (see sections 4.2 and 5.2 on recommended dose regimens and the effects of food on absorption). 
Še posebej pomembno je, da skušate zagotoviti doseganje največje plazemske koncentracije pri bolnikih, okuženih z Aspergillusom (glejte poglavji 4.2 in 5.2 o priporočenih režimih odmerjanja in učinkih hrane na absorpcijo).
H-1045 Budapest HUNGARY 
H-1045 Budimpešta Madžarska
H-1045 Budapest Hungary 
H-1045 Budimpešta MADŽARSKA
- Do not use this medicine after the expiry date which is stated on the label. 
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden naovojnini.
Clinical outcomes were compared with those in an external control group derived from a retrospective review of medical records. 
Klinične izide so primerjali z izidi zunanje kontrolneskupine, ki so jih dobilina osnovi retrospektivnega pregleda zdravstvene dokumentacije.
Epidemiological Cut-off (ECOFF) Values for Aspergillus spp. 
Epidemiološke mejnevrednosti (ECOFF) za Aspergillus spp.
PHARMACEUTICAL FORM AND CONTENTS Oral suspension 
FARMACEVTSKA OBLIKA IN VSEBINA peroralna suspenzija
The safety and efficacy of posaconazole in children aged below 18 years have not been established. 
Varnost in učinkovitost posakonazola pri otrocih, mlajših od 18 let, nista ugotovljeni.
Steady-state is attained following 7 to 10 days of multiple-dose administration. 
Stanjedinamičnegaravnovesja je doseženo po 7 do 10 dneh dajanja večkratnih odmerkov.
Clinical success rate was defined as the number of cases assessed as having a clinical response (cure or improvement) divided by the total number of cases eligible for analysis 
Kliničnauspešnost je bila opredeljena kot število primerov, pri katerih so ocenili pozitiven klinični odziv (ozdravitev ali izboljšanje stanja), deljeno s skupnim številom primerov, ki so bili primerni za analizo
fluconazole, itraconazole or voriconazole. 
flukonazol, itrakonazol ali vorikonazol.
The filled and sealed bottle is packed into a carton along with a graduated polystyrene spoon (2.5 mL and 5 mL) for dispensing and administration of the suspension. 
Napolnjena in zaprta steklenička je pakirana v škatli skupaj z označeno polistirensko žličko (z oznakama 2,5 ml in 5 ml) za odmerjanje in aplikacijo suspenzije.
Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine (< 0.2 % of the radiolabelled dose is parent compound). 
Ledvični očistek je manj pomembna pot izločanja;v urinu se izloči14 % radioaktivnooznačenega odmerka (< 0,2 % radioaktivno označenega odmerka predstavlja matična spojina).
The oral suspension must be shaken well before use. 
Način uporabe za peroralno uporabo Peroralno suspenzijo je treba pred uporabo dobro pretresti.
Clinical success rate at Day 14 Clinical success rate 4 weeks after end of treatment 
Odstotekklinične uspešnostina 14. dan Odstotekklinične uspešnosti4 tedne po koncu zdravljenja
This medicine contains less than 1 mmol sodium (23 mg) per 5 mL of suspension, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) v 5 ml suspenzije, kar v bistvu pomeni, da je »brez natrija«.
The external control group included 86 patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole. 
V zunanjikontrolni skupini je bilo 86 bolnikov,zdravljenih z razpoložljivimizdravili(kot navedeno zgoraj),večinoma ob istem času in na istih mestih kot bolniki,
Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution (1,774 litres) and is highly protein bound (> 98 %), predominantly to serum albumin. 
Posakonazolsepočasi absorbira in počasi izloča, z velikim navideznim porazdelitvenim volumnom(1.774 litrov) in je v veliki meri vezan na beljakovine (> 98 %), predvsem na serumski albumin.
The primary efficacy variable was the clinical success rate (defined as cure or improvement) after 14 days of treatment. 
Primarni parameter učinkovitosti je bilodstotek klinične uspešnosti(opredeljena kot ozdravitev ali izboljšanjestanja)po14 dneh zdravljenja.
The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology. 
ECOFF vrednosti za posakonazol, ki razlikujejopopulacijo divjega tipa od izolatovs pridobljenoodpornostjo, so bile določene po metodologijiEUCAST.
Food The absorption of posaconazole is significantly increased by food (see sections 4.2 and 5.2). 
Absorpcija posakonazola se bistveno poveča s hrano (glejte poglavji 4.2 in 5.2).
- If you have any suspension left in a bottle more than 30 days after it was first opened, you should not use this medicine. 
- Čevamveč kot 30 dni po prvem odprtju stekleničke vnjejostane še nekaj suspenzije, tegazdravila ne smete več uporabljati.
If you take more Posaconazole AHCL than you should If you are concerned that you may have taken too much, contact your doctor or healthcare professional immediately. 
Če ste vzeli večji odmerek zdravila Posakonazol AHCL, kot bi smeli Če vas skrbi, da ste morda zaužili preveč zdravila, nemudoma pokličite zdravnika ali zdravstvenegadelavca.
New diagnosis of acute myelogenous leukaemia was the most common underlying condition (435/602, [72 %]). 
Najpogostejša osnovna bolezen je bilana novo diagnosticirana akutna mieloična levkemija (435/602, [72%]).
There is no information on the effect of alcohol on posaconazole." 
Ni podatkov o vplivu alkohola na posakonazol.
LIST OF EXCIPIENTS Contains glucose. 
SEZNAM POMOŽNIH SNOVI Vsebuje glukozo.
Please make sure you tell your doctor about all the medicines you are taking (prescribed or non-prescribed). 
Zdravniku morate zato povedati za vsa zdravila, ki jih jemljete (tako za zdravila, ki ste jih dobili na recept, kot za takšna,ki ste jih dobili brez recepta).
Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb 
Kontrolnaskupinaa Odstotek (%) bolnikov z dokazano oziroma verjetno aspergilozo Obdobjezdravljenjab
There are currently insufficient data to set clinical breakpoints for Aspergillus spp. 
Trenutnoni dovolj podatkov za določitev kliničnih mejnih vrednosti za Aspergillus spp.
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Spain 
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Španija
The following medicines may decrease the effectiveness of Posaconazole AHCL by decreasing the amount of Posaconazole AHCL in the blood: - rifabutin and rifampicin (used to treat certain infections). 
Naslednja zdravila lahko zmanjšajo učinkovitost zdravila Posakonazol AHCL, ker zmanjšajo njegovo količino v krvi: - rifabutin in rifampicin (uporabljata se za zdravljenje določenih okužb).
EUCAST ECOFF values: - Aspergillus flavus: 0.5 mg/L - Aspergillus fumigatus: 0.25 mg/L - Aspergillus nidulans: 0.5 mg/L - Aspergillus niger: 0.5 mg/L - Aspergillus terreus: 0.25 mg/L 
EUCAST ECOFF vrednosti: - Aspergillusflavus: 0,5mg/l - Aspergillus fumigatus: 0,25mg/l - Aspergillus nidulans: 0,5mg/l - Aspergillusniger: 0,5mg/l - Aspergillusterreus: 0,25mg/l
- efavirenz and fosamprenavir used to treat HIV infection. 
- efavirenzinfosamprenavir,kise uporabljata za zdravljenje okužbe s HIV.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili
Administration of other azoles has been associated with increases in digoxin levels. 
Uporaba drugih azolov je bila povezana s povečanjemkoncentracij digoksina.
Discard after 30 days of opening. 
Zavrzite 30 dni po odprtju.
Prophylaxis of Invasive Fungal Infections (IFIs) (Studies 316 and 1899) Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections. 
Profilaksa invazivnih glivnih okužb (študiji 316 in 1899) Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za pojavinvazivnih glivnih okužb.
Additionally, twelve patients 13-17 years of age received posaconazole oral suspension 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899). 
Poleg tega je dvanajst bolnikov, starih od 13 do 17 let, prejemalo peroralno suspenzijo posakonazola v odmerku 600 mg/dan za profilakso invazivnih glivnih okužb (študiji316in 1899).
In Study 316, overall mortality was similar (POS, 25 %; FLU, 28 %); however, the proportion of IFIrelated deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413). 
Vštudiji316jebila celokupna umrljivost podobna (POS 25 %, FLU 28 %), vendar je bil odstotek zinvazivno glivno okužbo povezanih smrtiv skupini s POS značilno manjši (4/301) kot vskupini sFLU (12/299, p = 0,0413).
- medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors. 
- zdravila, ki se uporabljajo za zmanjševanje količine želodčne kisline, kot so cimetidin in ranitidin ali omeprazol ter podobna zdravila, ki jih imenujemo zaviralci protonske črpalke.
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders. 
Med osemnajstimibolniki, ki niso prenašaliamfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group (79 %). 
Večinaprimerovaspergiloze jeveljala za odporne na predhodno zdravljenje tako v skupini,kijeprejemalaposakonazol(88 %), kot v zunanji kontrolni skupini (79 %).
Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure. 
Farmakokinetično modeliranje z obliko peroralnih tablet kaže, da je lahko izpostavljenost posakonazolu manjša pri bolnikih, ki tehtajo več kot 120 kg.
Patients who develop abnormal liver function tests during Posaconazole AHCLtherapy must be routinely monitored for the development of more severe hepatic injury. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Posakonazol AHCL pojavijo nenormalni izvidi jetrnih testov, je treba rutinsko spremljati glede nastanka hujše poškodbe jeter.
As observed with other azole antifungal agents, these effects on reproduction were considered to be due to a treatment-related effect on steroidogenesis. 
Tako kot pri drugih azolskih antimikotikih so ti učinki na razmnoževanješteliza posledico z zdravljenjempovezanega učinka na steroidogenezo.
See “Other medicines and Posaconazole AHCL” below for more information including information on other medicines which may interact with Posaconazole AHCL. 
Glejte"DrugazdravilainzdraviloPosakonazol AHCL"(spodaj) za več informacij, vključno z informacijami odrugih zdravilih, ki lahko medsebojno delujejo z zdravilom Posakonazol AHCL.
In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16 %) vs. FLU/ITZ 67/298 (22 %) p= 0.048]. 
Vštudiji1899so značilno manjšo celokupno umrljivost zaradivsehvzrokovopazili v skupini, ki jeprejemala posakonazol [POS 49/304 (16 %) v primerjavi s FLU/ITZ67/298 (22 %), p = 0,048].
Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 1.4-fold and 4.6-fold greater, respectively, than those achieved with the human therapeutic doses. 
Zvišan sistolični in arterijski krvni tlak (do 29 mmHg) so opažali pri podganah oz. opicahpri sistemskih izpostavljenostih, ki so bile 1,4-krat oz. 4,6-krat večje od izpostavljenosti, doseženih sterapevtskimiodmerkipričloveku.
flatulence, constipation, anorectal discomfort 
flatulenca, konstipacija, anorektalno nelagodje
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. 
Rifabutin Posakonazolje povečal Cmaxrifabutina za 31%in AUC rifabutina za 72 %.
A measuring spoon is provided with each bottle for measuring 2.5 and 5 mL doses of the oral suspension. 
Vsaki steklenički je priložena odmerna žlička za odmerjanje 2,5 in 5ml peroralne suspenzije.
Posaconazole is a potent inhibitor of CYP3A4. 
Posakonazol je močan zaviralec CYP3A4.